全文获取类型
收费全文 | 255130篇 |
免费 | 17988篇 |
国内免费 | 1013篇 |
学科分类
医药卫生 | 274131篇 |
出版年
2023年 | 1300篇 |
2022年 | 914篇 |
2021年 | 5085篇 |
2020年 | 3234篇 |
2019年 | 5397篇 |
2018年 | 6494篇 |
2017年 | 4749篇 |
2016年 | 5155篇 |
2015年 | 6105篇 |
2014年 | 8870篇 |
2013年 | 12121篇 |
2012年 | 18481篇 |
2011年 | 19156篇 |
2010年 | 10685篇 |
2009年 | 9915篇 |
2008年 | 16956篇 |
2007年 | 17699篇 |
2006年 | 17235篇 |
2005年 | 17011篇 |
2004年 | 16108篇 |
2003年 | 14731篇 |
2002年 | 13949篇 |
2001年 | 2733篇 |
2000年 | 2254篇 |
1999年 | 2526篇 |
1998年 | 2621篇 |
1997年 | 2044篇 |
1996年 | 1793篇 |
1995年 | 1960篇 |
1994年 | 1714篇 |
1993年 | 1712篇 |
1992年 | 1565篇 |
1991年 | 1527篇 |
1990年 | 1350篇 |
1989年 | 1313篇 |
1988年 | 1212篇 |
1987年 | 1168篇 |
1986年 | 1126篇 |
1985年 | 1180篇 |
1984年 | 1270篇 |
1983年 | 1102篇 |
1982年 | 1240篇 |
1981年 | 1134篇 |
1980年 | 1015篇 |
1979年 | 803篇 |
1978年 | 693篇 |
1977年 | 625篇 |
1976年 | 620篇 |
1974年 | 544篇 |
1973年 | 484篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Victoria L. Parker Matthew C. Winter John A. Tidy Barry W. Hancock Julia E. Palmer Naveed Sarwar Baljeet Kaur Katie McDonald Xianne Aguiar Kamaljit Singh Nick Unsworth Imran Jabbar Allan A. Pacey Robert F. Harrison Michael J. Seckl 《International journal of cancer. Journal international du cancer》2023,152(5):986-997
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus. 相似文献
3.
4.
Kamolz Lars-Peter Kotzbeck Petra Schintler Michael Spendel Stephan 《European Surgery》2022,54(3):163-169
European Surgery - Large skin defects caused by trauma (e.g., burns) or due to other reasons (e.g., tumor-related skin resections) require sufficient skin replacement. The constant improvement of... 相似文献
5.
6.
Helmer Philipp Schlesinger Tobias Hottenrott Sebastian Papsdorf Michael Wöckel Achim Diessner Joachim Stumpner Jan Sitter Magdalena Skazel Tobias Wurmb Thomas Härtel Christoph Hofer Stefan Alkatout Ibrahim Girard Thierry Meybohm Patrick Kranke Peter 《Der Anaesthesist》2022,71(3):171-180
Die Anaesthesiologie - Die Implementierung eines Patient Blood Management (PBM) wird zunehmender Standard in der operativen Medizin. Seit einiger Zeit gilt das Interesse auch den vulnerablen... 相似文献
7.
8.
9.
Sounak Gupta Rafael E. Jimenez Loren Herrera-Hernandez Christine M. Lohse R. Houston Thompson Stephen A. Boorjian Bradley C. Leibovich John C. Cheville 《Mayo Clinic proceedings. Mayo Clinic》2021,96(6):1470-1489
ObjectiveTo study the clinical features and identify unique renal neoplasia subtypes and their prognostic implications in individuals with tuberous sclerosis complex (TSC).Patients and MethodsThe Mayo Clinic nephrectomy registry included 37 patients with TSC diagnosed between 1970 and 2018. Four additional patients were identified from the pathology consultation and autopsy files. All available renal tumors were further characterized using immunohistochemistry and fluorescence in situ hybridization. Clinicopathologic features and follow-up were obtained from the medical record. The American Association for Cancer Research Project GENIE registry was accessed using cBioPortal for molecular profiling of angiomyolipoma (AML).ResultsA total of 276 renal tumors from 41 patients were analyzed. Renal tumors were classified into 9 distinct morphological subtypes, with AML predominating (238 [86%]). Interestingly, all these tumors acted in a benign fashion except one renal cell carcinoma with clear cells and fibromyomatous stroma and one epithelioid AML that metastasized. Molecular profiling studies revealed that epithelioid AMLs were enriched for alterations of TP53, RB1, and ATRX. Eight patients died of direct complications of TSC, including 3 of end-stage renal disease. To date, none have died of a renal epithelial neoplasm.ConclusionThe identification of unique renal neoplasia subtypes may provide important clues to establish a diagnosis of TSC, and in the somatic setting, this finding has important implications for accurate prognostication. These tumors tend to be indolent, and only 2 of 276 tumors in our study exhibited metastatic behavior. Our results support multidisciplinary management with a focus on preservation of renal function. 相似文献
10.
Kerstin Folkerts Natalia Petruski-Ivleva Erin Comerford Michael Blankenburg Thomas Evers Alain Gay Linda Fried Csaba P. Kovesdy 《Mayo Clinic proceedings. Mayo Clinic》2021,96(4):975-986
ObjectiveTo examine the screening rates for kidney damage and function among patients with type 2 diabetes (T2D) and chronic kidney disease stage at diabetes diagnosis using a US administrative claims database.Patients and MethodsThis cohort study used a claims database enriched with laboratory results data. Patients with T2D (defined as 1 inpatient or 2 outpatient claims for diabetes), aged 18 years or older, and with at least 1 year of follow-up enrollment were identified. Patients with type 1 diabetes, kidney disease, or other related conditions at baseline were excluded. We estimated screening rates using laboratory orders for serum creatinine and estimated glomerular filtration rate (eGFR) measurement and urine albumin to creatinine ratio (UACR). Chronic kidney disease severity was reported using the Kidney Disease: Improving Global Outcomes classification based on laboratory results.ResultsA total of 1,881,447 patients with T2D were eligible for analysis. Mean ± SD age was 63.1±13.1 years; 947,150 patients (50.3%) were male. Serum creatinine tests were ordered within 14 days of the index date among 290,722 patients of 622,915 (46.7%) patients with newly-recognized T2D. Overall, 1,595,964 patients (84.8%) had at least one serum creatinine test ordered during the 1-year follow-up period. Fewer patients received a UACR test during follow-up (814,897 [43.3%]). Less than half of all patients with T2D received a laboratory test order for both serum creatinine and urine albumin measurements during the follow-up period.ConclusionPhysicians treating patients with diabetes are selectively adhering to chronic kidney disease screening guidelines, as indicated by high rates of eGFR testing, but less frequent UACR testing. Despite recommendations to monitor both eGFR and UACR, less than half of patients were screened for albuminuria during the 1-year follow-up. 相似文献